The potential role of ER beta isoforms in the clinical management of breast cancer

C A Green, M B Peter, V Speirs, A M Shaaban

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

Original languageEnglish
Pages (from-to)374-80
Number of pages7
JournalHistopathology
Volume53
Issue number4
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Protein Isoforms
Breast Neoplasms
Estrogen Receptor beta
Exons
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • Animals
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Estrogen Receptor beta
  • Female
  • Humans
  • Models, Genetic
  • Protein Isoforms
  • Structure-Activity Relationship
  • Treatment Outcome
  • Journal Article
  • Review

Cite this

The potential role of ER beta isoforms in the clinical management of breast cancer. / Green, C A; Peter, M B; Speirs, V; Shaaban, A M.

In: Histopathology, Vol. 53, No. 4, 10.2008, p. 374-80.

Research output: Contribution to journalReview article

Green, C A ; Peter, M B ; Speirs, V ; Shaaban, A M. / The potential role of ER beta isoforms in the clinical management of breast cancer. In: Histopathology. 2008 ; Vol. 53, No. 4. pp. 374-80.
@article{53e4e0ec6fb74429b829ed979f8689be,
title = "The potential role of ER beta isoforms in the clinical management of breast cancer",
abstract = "The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.",
keywords = "Animals, Antineoplastic Agents, Hormonal, Breast Neoplasms, Estrogen Receptor beta, Female, Humans, Models, Genetic, Protein Isoforms, Structure-Activity Relationship, Treatment Outcome, Journal Article, Review",
author = "Green, {C A} and Peter, {M B} and V Speirs and Shaaban, {A M}",
year = "2008",
month = "10",
doi = "10.1111/j.1365-2559.2008.02968.x",
language = "English",
volume = "53",
pages = "374--80",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Blackwell Publishing",
number = "4",

}

TY - JOUR

T1 - The potential role of ER beta isoforms in the clinical management of breast cancer

AU - Green, C A

AU - Peter, M B

AU - Speirs, V

AU - Shaaban, A M

PY - 2008/10

Y1 - 2008/10

N2 - The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

AB - The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

KW - Animals

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Estrogen Receptor beta

KW - Female

KW - Humans

KW - Models, Genetic

KW - Protein Isoforms

KW - Structure-Activity Relationship

KW - Treatment Outcome

KW - Journal Article

KW - Review

U2 - 10.1111/j.1365-2559.2008.02968.x

DO - 10.1111/j.1365-2559.2008.02968.x

M3 - Review article

C2 - 18312354

VL - 53

SP - 374

EP - 380

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 4

ER -